IRB #

STUDY00019279

Title

A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Principal Investigator

Jacqueline Vuky

Study Purpose

We are doing this study because we want to find out if ipatasertib in combination with paclitaxel (a common type of chemotherapy) is a better treatment for your type of breast cancer than paclitaxel alone.

Medical Condition(s)

Breast Cancer, Hormones

Eligibility Criteria

Triple-negative breast cancer (TNBC) or hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2−) that has spread.

Confirmation eligibility through testing of tumor tissue or blood.

Age Range

18 - 120

Healthy Volunteers Needed

No

Duration of Participation

Up to 53 months, including follow up time.

Minors Included

No

Contact

OHSU Knight Cancer Institute Clinical Trials Info Line:
Phone: 503-494-1080
Email: trials@ohsu.edu

Sponsor

F. Hoffmann-La Roche Ltd.

Recruitment End

12/24/2021

Compensation Provided

No


Go Back